Carcinotech specializes in innovative cancer research through its proprietary Carcino3D™ technology, which focuses on the creation of 3D printed living tumors derived from patient-specific biopsies, primary cells, immune cells, and cancer stem cells. This advanced technology enables rapid and ethical drug discovery, screening, and pre-clinical testing, providing a platform that closely mimics the heterogeneity of actual tumors. The printed tumors are designed to be assay-ready, allowing for high-throughput testing and robust results, which are crucial for the development of personalized cancer treatments. Carcinotech collaborates with global partners, including pharmaceutical companies and healthcare professionals, to enhance the efficacy of cancer therapies.

In addition to drug discovery, Carcinotech's Carcino3D™ technology plays a significant role in personalized medicine. By utilizing molecular and phenotypic data from patients, the technology aids in tailoring treatment plans based on the specific characteristics of an individual's tumor. This precision medicine approach not only helps in diagnosing and planning treatments but also in monitoring treatment efficacy and making prognostic assessments. The ability to customize printed tumors according to various patient-specific factors, such as mutation types and drug targets, further enhances the potential for successful treatment outcomes in oncology.

United Kingdom

Carcinotech provides comprehensive solid tumour research services to therapeutic developers and healthcare professionals. At the heart of its offerings is the proprietary Carcino3D™ bioprinting platform, which creates assay-ready, 3D tumours from patient biopsies. 

Unlike conventional cancer models, Carcinotech’s bioprinted constructs incorporate multiple cell types—including immune cell populations—within a robust tissue matrix, offering a more biologically relevant and controlled model for early drug discovery, preclinical and co-clinical studies, and personalised treatment testing.

Carcinotech

Company Details